01 — At a Glance
The Expensive Biotech Gamble That Hasn’t Landed Yet
- 52-Week High / Low₹425 / ₹295
- Q3 FY26 Revenue₹4,173 Cr
- Q3 FY26 PAT-₹52 Cr (Loss)
- Q3 FY26 EPS₹1.08
- TTM Full-Year EPS₹4.81
- Book Value₹200
- Price to Book1.95x
- Dividend Yield0.13%
- Debt / Equity0.62x
- BBL Integration₹5.5 Bn Valuation
Auditor’s Note: Biocon’s Q3 FY26 reads like a company in metamorphosis. Revenue at ₹4,173 crore (+9% YoY). Core EBITDA margin blooming to 29%. But reported PAT: a loss of ₹52 crore because of acquisition-related fair value adjustments and interest costs. The stock prices in a unicorn exit but delivers single-digit RoE and 6% ROCE. Biocon Biologics acquisition valued at $5.5 billion (~₹50,000 crore) is scheduled to close by March 2026. Two QIPs totalling ₹8,650 crore have been raised to fund it. The narrative is “high-growth pharma with global ambitions.” The valuation is “we believe you.”
02 — Introduction
Welcome to the Messiest Wealth Creation Story in Pharma
Biocon is a 46-year-old Indian biopharma company that set out to become a global innovator and has become a global acquirer instead. Founded in 1978 by Kiran Mazumdar Shaw (currently 44.91% promoter stake), it started as a biotech R&D shop and has metamorphosed into a three-legged beast: biosimilars (58% of revenue), generics (19%), and contract research services via Syngene (23%).
In December 2019, Biocon acquired the biosimilars business of Viatris for $1.2 billion — funded through a combination of debt and structured instruments. This single transaction tripled the ambition but also tripled the complexity. Jump to December 2025, and Biocon is now acquiring 100% of Biocon Biologics (the wholly-owned biosimilars JV) through a $5.5 billion all-in transaction. The deal involves a ₹4,150 crore QIP (already done in January 2026) and a second QIP of ₹4,500 crore planned for March 2026.
The concall in February 2026 dripped with ambition: interchangeable insulin biosimilars, GLP-1 generics in the US, oncology biosimilars against therapies representing a $75 billion market. The language was “Biocon 2.0” — a single integrated biopharma platform where “governance simplifies, capital allocation tightens, and cash flows consolidate.”
But here’s the kicker: despite all this, the company’s ROCE is 6.25%, ROE is 4.94% (3-year average), and the stock trades at 77.1x earnings. That’s not visionary. That’s a valuation asking the market to believe in a future that hasn’t been priced by the business’s current earning power. Let’s unhinge this carefully.
Concall Highlight (Feb 2026): “Future is more exciting than what the past has been.” Biocon management, essentially admitting the past 5 years have been rough. Honesty we can respect.
03 — Business Model: Three Legs, One Prayer
Biosimilars, Generics, and CRDMO Services Walk Into a Bar
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
